KDR and non-small cell lung carcinoma: Several anti-angiogenesis targeted drugs for VEGFA and its receptor (VEGFR2) have been developed such as the bevacizumab and ramucirumab which could be used for advanced non-small cell lung cancer (NSCLC) [43, 45].